Skip to main content
Premium Trial:

Request an Annual Quote

ArcherDx, Illumina Agree to Comarket Future IVDs

NEW YORK – ArcherDx said on Friday that it has signed a non-exclusive, multiyear partnership with Illumina intended to broaden access to next-generation sequencing oncology testing, including — upon regulatory approval — companion diagnostics for therapeutic selection, personalized monitoring, and new recurrence surveillance in vitro diagnostics.

The company said the agreement expands and builds upon other existing collaborations with Illumina, including partnerships to develop ArcherDx IVD tests to run on Illumina's NextSeq 550Dx and MiSeq Dx systems and an agreement to comarket and copromote the Archer FusionPlex line of research products in markets outside the United States.

Under the new agreement the companies will also co-market future ArcherDx IVDs alongside the NextSeq 550Dx and MiSeq Dx instruments. According to ArcherDx, the first of these new clinical assays is likely to be the ArcherDx Stratafide companion diagnostic.

Stratafide is a pan-solid tumor test designed to identify actionable genomic alterations in tissue or blood samples, including targets of both approved drugs and emerging therapies undergoing clinical trials. It was granted US Food and Drug Administration breakthrough device designation in early 2019.

Following FDA approval of Stratafide, ArcherDx said it also plans to seek regulatory approval for its Personalized Cancer Monitoring (PCM) product, designed to assess therapy success and identify early signs of disease recurrence.

The goal in linking its tests to the increasingly omnipresent Illumina installed base, ArcherDx said, is to help more patients access precision medicine by increasing local, decentralized options across community practices.

"Illumina's NGS instruments are ubiquitous in thousands of clinical and research settings due to their accuracy, speed and user experience. That technology, together with our planned IVD test kits and companion software, will allow these platforms to guide clinical decision-making and targeted therapy," ArcherDx CEO Jason Myers said in a statement.

"We are pleased to take this next step in our commercial partnership to support expanding access to leading-edge genomic cancer management to more patients, in more communities, to improve patient outcomes," added Illumina CMO Phil Febbo.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.